RE:RE:RE:RE:RE:RE:biogen suffering ? M101 wrote: I hope she leverages the modest benefit of lecanemab into a promotional strategy that stresses PMN310s differences rather than similarities. It's almost October, the baseball analogies practically write themselves. Lecanemab is a longer pop fly than Aducanumab, but they're both outs. Credit the player with making contact as opposed to all the earlier whiffs, but outs are still how you lose.
The difference with PMN310 has always been there. Targetting toxic oligomers. It can't be clearer than that. ProMIS has always made that very plain. Selectivity!
The jury is still out for Lecanemab.
Looks good though in keeping the amyloid-beta hypothesis alive.
G1945V